Bellevue Life Sciences Acquisition (BLAC) Competitors $1.78 -0.51 (-22.27%) As of 03/10/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrends BLAC vs. DXR, CLGN, POCI, FEMY, OM, NMTC, NXL, PYPD, MODD, and COCHShould you be buying Bellevue Life Sciences Acquisition stock or one of its competitors? The main competitors of Bellevue Life Sciences Acquisition include Daxor (DXR), CollPlant Biotechnologies (CLGN), Precision Optics (POCI), Femasys (FEMY), Outset Medical (OM), NeuroOne Medical Technologies (NMTC), Nexalin Technology (NXL), PolyPid (PYPD), Modular Medical (MODD), and Envoy Medical (COCH). These companies are all part of the "medical equipment" industry. Bellevue Life Sciences Acquisition vs. Daxor CollPlant Biotechnologies Precision Optics Femasys Outset Medical NeuroOne Medical Technologies Nexalin Technology PolyPid Modular Medical Envoy Medical Bellevue Life Sciences Acquisition (NASDAQ:BLAC) and Daxor (NASDAQ:DXR) are both small-cap unclassified companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability. Does the media prefer BLAC or DXR? In the previous week, Daxor had 7 more articles in the media than Bellevue Life Sciences Acquisition. MarketBeat recorded 7 mentions for Daxor and 0 mentions for Bellevue Life Sciences Acquisition. Daxor's average media sentiment score of 0.23 beat Bellevue Life Sciences Acquisition's score of 0.00 indicating that Daxor is being referred to more favorably in the news media. Company Overall Sentiment Bellevue Life Sciences Acquisition Neutral Daxor Neutral Do analysts recommend BLAC or DXR? Daxor has a consensus price target of $24.75, suggesting a potential upside of 205.56%. Given Daxor's stronger consensus rating and higher possible upside, analysts plainly believe Daxor is more favorable than Bellevue Life Sciences Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bellevue Life Sciences Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Daxor 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BLAC or DXR more profitable? Company Net Margins Return on Equity Return on Assets Bellevue Life Sciences AcquisitionN/A N/A N/A Daxor N/A N/A N/A Which has more volatility and risk, BLAC or DXR? Bellevue Life Sciences Acquisition has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Which has stronger earnings & valuation, BLAC or DXR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/ADaxor$2.13M18.39N/AN/AN/A Does the MarketBeat Community prefer BLAC or DXR? Daxor received 1 more outperform votes than Bellevue Life Sciences Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformBellevue Life Sciences AcquisitionN/AN/ADaxorOutperform Votes1100.00% Underperform VotesNo Votes Do insiders and institutionals have more ownership in BLAC or DXR? 55.3% of Bellevue Life Sciences Acquisition shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 33.7% of Bellevue Life Sciences Acquisition shares are owned by insiders. Comparatively, 59.0% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryDaxor beats Bellevue Life Sciences Acquisition on 8 of the 10 factors compared between the two stocks. Remove Ads Get Bellevue Life Sciences Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for BLAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLAC vs. The Competition Export to ExcelMetricBellevue Life Sciences AcquisitionHolding Offices IndustryUnclassified SectorNASDAQ ExchangeMarket Cap$9.25M$459.14M$127.26M$7.97BDividend YieldN/A7.18%N/A4.03%P/E RatioN/A2.191.2118.86Price / SalesN/A64.4518.37113.80Price / CashN/A69.0193.7934.62Price / BookN/A3.740.864.13Net IncomeN/A$35.78M$1.63M$246.59M7 Day Performance-11.92%-1.32%0.11%-2.44%1 Month Performance-63.71%-5.45%-2.35%-9.44%1 Year Performance-78.48%7.66%18.05%-0.89% Bellevue Life Sciences Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLACBellevue Life Sciences AcquisitionN/A$1.78-22.3%N/A-78.5%$7.19MN/A0.00N/AGap UpHigh Trading VolumeDXRDaxor3.758 of 5 stars$7.77+0.9%$24.75+218.5%-1.9%$37.58M$2.61M0.0037CLGNCollPlant Biotechnologies2.9522 of 5 stars$3.11-8.5%$12.50+301.9%-35.3%$35.63M$650,000.00-2.0270Gap DownPOCIPrecision Optics0.7735 of 5 stars$4.49-0.3%N/A-21.2%$34.25M$18.68M-7.0180Positive NewsGap DownFEMYFemasys2.3106 of 5 stars$1.46-5.2%$10.00+584.9%-31.4%$33.43M$1.26M-1.8030Gap DownOMOutset Medical1.2566 of 5 stars$0.61-8.5%$4.50+636.5%-80.8%$32.87M$113.69M-0.25520NMTCNeuroOne Medical Technologies0.1513 of 5 stars$1.03-4.2%N/A-25.2%$31.67M$5.75M-3.9520News CoverageNXLNexalin Technology2.341 of 5 stars$2.35-2.7%$3.00+27.4%+322.4%$31.34M$162,078.00-3.683PYPDPolyPid1.6689 of 5 stars$3.00+1.4%$11.33+277.8%-49.7%$30.57MN/A-0.6080News CoverageMODDModular Medical2.2858 of 5 stars$0.73-5.6%$5.00+589.7%-55.9%$29.48MN/A-1.3720Gap UpCOCHEnvoy Medical2.112 of 5 stars$1.39+4.4%$8.00+476.0%-85.2%$27.92M$278,000.000.0034News CoveragePositive News Remove Ads Related Companies and Tools Related Companies DXR Competitors CLGN Competitors POCI Competitors FEMY Competitors OM Competitors NMTC Competitors NXL Competitors PYPD Competitors MODD Competitors COCH Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BLAC) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellevue Life Sciences Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellevue Life Sciences Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
